Literature DB >> 35372989

Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: CON.

Anne-Els van de Logt1, Jack F Wetzels1.   

Abstract

Entities:  

Keywords:  cyclophosphamide; glomerular and tubulointerstitial diseases; membranous; membranous glomerulonephritis; nephrotic syndrome; rituximab

Mesh：

Substances：

Year:  2021        PMID： 35372989      PMCID： PMC8785842          DOI： 10.34067/KID.0001432021

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  16 in total

1.  Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy.

Authors:  Jan A J G van den Brand; Peter R van Dijk; Julia M Hofstra; Jack F M Wetzels
Journal:  J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 10.121

2.  Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.

Authors:  Fernando C Fervenza; Gerald B Appel; Sean J Barbour; Brad H Rovin; Richard A Lafayette; Nabeel Aslam; Jonathan A Jefferson; Patrick E Gipson; Dana V Rizk; John R Sedor; James F Simon; Ellen T McCarthy; Paul Brenchley; Sanjeev Sethi; Carmen Avila-Casado; Heather Beanlands; John C Lieske; David Philibert; Tingting Li; Lesley F Thomas; Dolly F Green; Luis A Juncos; Lada Beara-Lasic; Samuel S Blumenthal; Amy N Sussman; Stephen B Erickson; Michelle Hladunewich; Pietro A Canetta; Lee A Hebert; Nelson Leung; Jay Radhakrishnan; Heather N Reich; Samir V Parikh; Debbie S Gipson; Dominic K Lee; Bruno R da Costa; Peter Jüni; Daniel C Cattran
Journal:  N Engl J Med       Date:  2019-07-04       Impact factor: 91.245

3.  Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial.

Authors:  M Praga; V Barrio; G Fernández Juárez; J Luño
Journal:  Kidney Int       Date:  2007-03-21       Impact factor: 10.612

4.  Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.

Authors:  Jan A J G van den Brand; Piero Ruggenenti; Antonietta Chianca; Julia M Hofstra; Annalisa Perna; Barbara Ruggiero; Jack F M Wetzels; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2017-05-09       Impact factor: 10.121

5.  Benefit and cost from the long-term use of cyclosporine-A in idiopathic membranous nephropathy.

Authors:  Pantelitsa Kalliakmani; Eleni Koutroulia; Florentia Sotsiou; John G Vlachojannis; Dimitrios S Goumenos
Journal:  Nephrology (Carlton)       Date:  2010-12       Impact factor: 2.506

6.  A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.

Authors:  Vivekanand Jha; Anirban Ganguli; Tarun K Saha; Harbir S Kohli; Kamal Sud; Krishan L Gupta; Kusum Joshi; Vinay Sakhuja
Journal:  J Am Soc Nephrol       Date:  2007-05-09       Impact factor: 10.121

7.  A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.

Authors:  C Ponticelli; P Zucchelli; P Passerini; B Cesana; F Locatelli; S Pasquali; M Sasdelli; B Redaelli; C Grassi; C Pozzi
Journal:  Kidney Int       Date:  1995-11       Impact factor: 10.612

8.  The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy.

Authors:  D S Goumenos; P Kalliakmani; S Tsakas; F Sotsiou; J G Vlachojannis
Journal:  Clin Nephrol       Date:  2004-01       Impact factor: 0.975

9.  Rituximab for idiopathic membranous nephropathy: who can benefit?

Authors:  Piero Ruggenenti; Carlos Chiurchiu; Mauro Abbate; Annalisa Perna; Paolo Cravedi; Mario Bontempelli; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2006-06-14       Impact factor: 8.237

10.  Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.

Authors:  Piero Ruggenenti; Hanna Debiec; Barbara Ruggiero; Antonietta Chianca; Timothee Pellé; Flavio Gaspari; Flavio Suardi; Elena Gagliardini; Silvia Orisio; Ariela Benigni; Pierre Ronco; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2015-03-24       Impact factor: 10.121
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.